| Id |
Subject |
Object |
Predicate |
Lexical cue |
| T1 |
0-133 |
Sentence |
denotes |
Risks and benefits of COX-2 inhibitors vs non-selective NSAIDs: does their cardiovascular risk exceed their gastrointestinal benefit? |
| T2 |
134-163 |
Sentence |
denotes |
A retrospective cohort study. |
| T3 |
164-175 |
Sentence |
denotes |
OBJECTIVES: |
| T4 |
176-371 |
Sentence |
denotes |
The risk of acute myocardial infarction (AMI) with COX-2 inhibitors may offset their gastrointestinal (GI) benefit compared with non-selective (NS) non-steroidal anti-inflammatory drugs (NSAIDs). |
| T5 |
372-520 |
Sentence |
denotes |
We aimed to compare the risks of hospitalization for AMI and GI bleeding among elderly patients using COX-2 inhibitors, NS-NSAIDs and acetaminophen. |
| T6 |
521-529 |
Sentence |
denotes |
METHODS: |
| T7 |
530-702 |
Sentence |
denotes |
We conducted a retrospective cohort study using administrative data of patients > or =65 years of age who filled a prescription for NSAID or acetaminophen during 1999-2002. |
| T8 |
703-784 |
Sentence |
denotes |
Outcomes were compared using Cox regression models with time-dependent exposures. |
| T9 |
785-793 |
Sentence |
denotes |
RESULTS: |
| T10 |
794-851 |
Sentence |
denotes |
Person-years of exposure among non-users of aspirin were: |
| T11 |
852-942 |
Sentence |
denotes |
75,761 to acetaminophen, 42,671 to rofecoxib 65,860 to celecoxib, and 37,495 to NS-NSAIDs. |
| T12 |
943-977 |
Sentence |
denotes |
Among users of aspirin, they were: |
| T13 |
978-1067 |
Sentence |
denotes |
14,671 to rofecoxib, 22,875 to celecoxib, 9,832 to NS-NSAIDs and 38,048 to acetaminophen. |
| T14 |
1068-1377 |
Sentence |
denotes |
Among non-users of aspirin, the adjusted hazard ratios (95% confidence interval) of hospitalization for AMI/GI vs the acetaminophen (with no aspirin) group were: rofecoxib 1.27 (1.13, 1.42), celecoxib 0.93 (0.83, 1.03), naproxen 1.59 (1.31, 1.93), diclofenac 1.17 (0.99, 1.38) and ibuprofen 1.05 (0.74, 1.51). |
| T15 |
1378-1593 |
Sentence |
denotes |
Among users of aspirin, they were: rofecoxib 1.73 (1.52, 1.98), celecoxib 1.34 (1.19, 1.52), ibuprofen 1.51 (0.95, 2.41), diclofenac 1.69 (1.35, 2.10), naproxen 1.35 (0.97, 1.88) and acetaminophen 1.29 (1.17, 1.42). |
| T16 |
1594-1605 |
Sentence |
denotes |
CONCLUSION: |
| T17 |
1606-1696 |
Sentence |
denotes |
Among non-users of aspirin, naproxen seemed to carry the highest risk for AMI/GI bleeding. |
| T18 |
1697-1829 |
Sentence |
denotes |
The AMI/GI toxicity of celecoxib was similar to that of acetaminophen and seemed to be better than those of rofecoxib and NS-NSAIDs. |
| T19 |
1830-1911 |
Sentence |
denotes |
Among users of aspirin, both celecoxib and naproxen seemed to be the least toxic. |
